Monocyte Subset Distribution in Patients with Stable Atherosclerosis and Elevated Levels of Lipoprotein(a)

Overview

Journal J Clin Lipidol

Publisher Elsevier

Specialties Biochemistry
Endocrinology

Date 2015 Aug 1

PMID 26228671

Citations 16

Authors

Konstantin A Krychtiuk

Stefan P Kastl

Sebastian L Hofbauer

Anna Wonnerth

Georg Goliasch

Maria Ozsvar-Kozma

Katharina M Katsaros

Gerald Maurer

Kurt Huber

Elisabeth Dostal

Christoph J Binder

Stefan Pfaffenberger

Stanislav Oravec

Johann Wojta

Walter S Speidl

Affiliations

Soon will be listed here.

Abstract

Background: Lipoprotein(a) (Lp(a)) is a proatherogenic plasma lipoprotein currently established as an independent risk factor for the development of atherosclerotic disease and as a predictor for acute thrombotic complications. In addition, Lp(a) is the major carrier of proinflammatory oxidized phospholipids (OxPL). Today, atherosclerosis is considered to be an inflammatory disease of the vessel wall in which monocytes and monocyte-derived macrophages are crucially involved. Circulating monocytes can be divided according to their surface expression pattern of CD14 and CD16 into at least 3 subsets with distinct inflammatory and atherogenic potential.

Objective: The aim of this study was to examine whether elevated levels of Lp(a) and OxPL on apolipoprotein B-100-containing lipoproteins (OxPL/apoB) are associated with changes in monocyte subset distribution.

Methods: We included 90 patients with stable coronary artery disease. Lp(a) and OxPL/apoB were measured, and monocyte subsets were identified as classical monocytes (CMs; CD14++CD16-), intermediate monocytes (IMs; CD14++CD16+), and nonclassical monocytes (NCMs; CD14+CD16++) by flow cytometry.

Results: In patients with elevated levels of Lp(a) (>50 mg/dL), monocyte subset distribution was skewed toward an increase in the proportion of IM (7.0 ± 3.8% vs 5.2 ± 3.0%; P = .026), whereas CM (82.6 ± 6.5% vs 82.0 ± 6.8%; P = .73) and NCM (10.5 ± 5.3 vs 12.8 ± 6.0; P = .10) were not significantly different. This association was independent of clinical risk factors, choice of statin treatment regime, and inflammatory markers. In addition, OxPL/apoB was higher in patients with elevated Lp(a) and correlated with IM but not CM and NCM.

Conclusions: In conclusion, we provide a potential link between elevated levels of Lp(a) and a proatherogenic distribution of monocyte subtypes in patients with stable atherosclerotic disease.

Citing Articles

Effect of PCSK9 Inhibitors on Regulators of Lipoprotein Homeostasis, Inflammation and Coagulation.

Lunar P, Meglic H, Vehar M, Ugovsek S, Rehberger Likozar A, Sebestjen M Biomedicines. 2025; 13(2).

PMID: 40002707 PMC: 11852752. DOI: 10.3390/biomedicines13020294.

Association of elevated circulating monocyte-platelet aggregates with hypercoagulability in patients with nephrotic syndrome.

Na S, Ning M, Ma J, Liang S, Wang Y, Sui M Thromb J. 2024; 22(1):56.

PMID: 38943162 PMC: 11212416. DOI: 10.1186/s12959-024-00626-3.

Association of Lipoprotein(a) with peri-coronary inflammation in persons with and without HIV infection.

Zisman E, Hossain M, Funderburg N, Christenson R, Jeudy J, Burrowes S J Clin Lipidol. 2024; 18(3):e430-e443.

PMID: 38403541 PMC: 11209819. DOI: 10.1016/j.jacl.2024.02.003.

Circulating intermediate monocytes CD14++CD16+ are increased after elective percutaneous coronary intervention.

Merinopoulos I, Bhalraam U, Holmes T, Tsampasian V, Corballis N, Gunawardena T PLoS One. 2023; 18(12):e0294746.

PMID: 38096193 PMC: 10721025. DOI: 10.1371/journal.pone.0294746.

Intermediate Monocytes and Circulating Endothelial Cells: Interplay with Severity of Atherosclerosis in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus.

Kologrivova I, Suslova T, Koshelskaya O, Kravchenko E, Kharitonova O, Romanova E Biomedicines. 2023; 11(11).

PMID: 38001912 PMC: 10669450. DOI: 10.3390/biomedicines11112911.

References

Miles L, Plow E . Lp(a): an interloper into the fibrinolytic system?. Thromb Haemost. 1990; 63(3):331-5. View

Kamstrup P . Lipoprotein(a) and ischemic heart disease--a causal association? A review. Atherosclerosis. 2010; 211(1):15-23. DOI: 10.1016/j.atherosclerosis.2009.12.036. View

Rifai N, Warnick G, McNamara J, Belcher J, Grinstead G, Frantz Jr I . Measurement of low-density-lipoprotein cholesterol in serum: a status report. Clin Chem. 1992; 38(1):150-60. View

Clarke R, Peden J, Hopewell J, Kyriakou T, Goel A, Heath S . Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009; 361(26):2518-28. DOI: 10.1056/NEJMoa0902604. View

Chistiakov D, Bobryshev Y, Nikiforov N, Elizova N, Sobenin I, Orekhov A . Macrophage phenotypic plasticity in atherosclerosis: The associated features and the peculiarities of the expression of inflammatory genes. Int J Cardiol. 2015; 184:436-445. DOI: 10.1016/j.ijcard.2015.03.055. View

Kashiwagi M, Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Ozaki Y . Association of monocyte subsets with vulnerability characteristics of coronary plaques as assessed by 64-slice multidetector computed tomography in patients with stable angina pectoris. Atherosclerosis. 2010; 212(1):171-6. DOI: 10.1016/j.atherosclerosis.2010.05.004. View

Kadl A, Meher A, Sharma P, Lee M, Doran A, Johnstone S . Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ Res. 2010; 107(6):737-46. PMC: 2941538. DOI: 10.1161/CIRCRESAHA.109.215715. View

Cros J, Cagnard N, Woollard K, Patey N, Zhang S, Senechal B . Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity. 2010; 33(3):375-86. PMC: 3063338. DOI: 10.1016/j.immuni.2010.08.012. View

Imanishi T, Ikejima H, Tsujioka H, Kuroi A, Ishibashi K, Komukai K . Association of monocyte subset counts with coronary fibrous cap thickness in patients with unstable angina pectoris. Atherosclerosis. 2010; 212(2):628-35. DOI: 10.1016/j.atherosclerosis.2010.06.025. View

10.

Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart D . Nomenclature of monocytes and dendritic cells in blood. Blood. 2010; 116(16):e74-80. DOI: 10.1182/blood-2010-02-258558. View

11.

Coen P, Flynn M, Markofski M, Pence B, Hannemann R . Adding exercise to rosuvastatin treatment: influence on C-reactive protein, monocyte toll-like receptor 4 expression, and inflammatory monocyte (CD14+CD16+) population. Metabolism. 2010; 59(12):1775-83. DOI: 10.1016/j.metabol.2010.05.002. View

12.

Nordestgaard B, Chapman M, Ray K, Boren J, Andreotti F, Watts G . Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010; 31(23):2844-53. PMC: 3295201. DOI: 10.1093/eurheartj/ehq386. View

13.

Catapano A, Reiner Z, De Backer G, Graham I, Taskinen M, Wiklund O . ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011; 217(1):3-46. DOI: 10.1016/j.atherosclerosis.2011.06.028. View

14.

Poitou C, Dalmas E, Renovato M, Benhamo V, Hajduch F, Abdennour M . CD14dimCD16+ and CD14+CD16+ monocytes in obesity and during weight loss: relationships with fat mass and subclinical atherosclerosis. Arterioscler Thromb Vasc Biol. 2011; 31(10):2322-30. DOI: 10.1161/ATVBAHA.111.230979. View

15.

Belge K, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B . The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol. 2002; 168(7):3536-42. DOI: 10.4049/jimmunol.168.7.3536. View

16.

Ancuta P, Rao R, Moses A, Mehle A, Shaw S, Luscinskas F . Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med. 2003; 197(12):1701-7. PMC: 2193954. DOI: 10.1084/jem.20022156. View

17.

Schlitt A, Heine G, Blankenberg S, Espinola-Klein C, Dopheide J, Bickel C . CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thromb Haemost. 2004; 92(2):419-24. DOI: 10.1160/TH04-02-0095. View

18.

KATTERMANN R, Jaworek D, Moller G, Assmann G, Bjorkhem I, Svensson L . Multicentre study of a new enzymatic method of cholesterol determination. J Clin Chem Clin Biochem. 1984; 22(3):245-51. DOI: 10.1515/cclm.1984.22.3.245. View

19.

Dowton S, Colten H . Acute phase reactants in inflammation and infection. Semin Hematol. 1988; 25(2):84-90. View

20.

Miles L, Fless G, Levin E, Scanu A, Plow E . A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 1989; 339(6222):301-3. DOI: 10.1038/339301a0. View